Gain a refresher/update on the technical aspects specific to the regulation of rDNA derived medicinal products
Improve your knowledge of the differences between the regulation of rDNA products and conventional small molecule drugs
Compare experiences with delegates from across Europe
* Please note the seminar assumes a scientific background and a basic knowledge of drug regulatory affairs WHO SHOULD ATTEND?
Life scientists moving into biotech regulatory affairs
Technical and scientific decision makers in biotech start up operations
Those with a life science background in the financial sector involved in due diligence or regulatory portfolio
Those from small molecule backgrounds transferring to biotech product regulatory affairs
Past Events
THE REGULATION OF rDNA TECHNOLOGY DERIVED DRUGS: BIOTECH SPECIFIC ASPECTS - 11 Mar 2010, The Rembrandt Hotel, London, United Kingdom (1570)
THE REGULATION OF rDNA TECHNOLOGY DERIVED DRUGS: BIOTECH SPECIFIC ASPECTS 2026
Important
Please, check "THE REGULATION OF rDNA TECHNOLOGY DERIVED DRUGS: BIOTECH SPECIFIC ASPECTS" official website for possible changes, before making any traveling arrangements
